Ann Transl Med. 2015 May;3:S40. doi: 10.3978/j.issn.2305-5839.2015.03.35.
Annals of translational medicine
Kresimir Oremus
PMID: 26046088 PMCID: PMC4437933 DOI: 10.3978/j.issn.2305-5839.2015.03.35
The Journal of Arthroplasty recently published a paper entitled "The Efficacy of Combined Use of Intraarticular and Intravenous Tranexamic Acid on Reducing Blood Loss and Transfusion Rate in Total Knee Arthroplasty". Tranexamic acid (TXA) is an antifibrinolytic drug whose administration during the perioperative period either by intravenous route or topically applied to the surgical field has been shown to reliably reduce blood loss and need for transfusion in patients undergoing total knee arthroplasty (TKA). Although randomized trials and meta-analyses did not show an increase in thromboembolic events, concerns remain about its repeated systemic application. The authors of the study introduced a novel regimen of TXA administration combining a preoperative intravenous bolus followed by local infiltration at the end of surgery with the idea of maximizing drug concentration at the surgical site while minimizing systemic antifibrinolytic effects. The combined dosage regimen appears to be more effective than single dose local application in reducing blood loss and transfusion rate without any complications noted.
Keywords: Total knee arthroplasty (TKA); systemic; topical; tranexamic acid (TXA)
